| MET |
Report |
Adjusted EPS |
BEAT |
pred ~$2.42 vs. cons $2.33 |
MEDIUM |
| MET |
Report |
Variable investment income (VII, pretax) |
BEAT |
pred ~$460M vs. cons ~$380M |
MEDIUM |
| MET |
Report |
Group Benefits group life mortality ratio |
BEAT |
pred ~82% vs. cons ~84% (lower = favorable) |
LOW |
| MET |
Guide |
FY26 RIS adjusted earnings guide |
UNCHANGED |
guide ~$1.6–1.8B reaffirmed vs. cons ~$1.7B (FY2026) |
MEDIUM |
| MET |
Guide |
FY26 direct expense ratio |
BETTER |
guide ~11.9% vs. cons/target 12.1% (FY2026) |
MEDIUM |
| MET |
Guide |
Q2 buyback / capital return pace |
BETTER |
pred ~$700M vs. cons ~$600M (Q2 2026) |
LOW |
| MET |
Guide |
Adjusted ROE |
UNCHANGED |
pred ~16.8% vs. cons ~16.5%, top of 15–17% target (FY2026) |
MEDIUM |
| MET |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| MET |
Return |
5-day cumulative residual |
-2.5% (FADE) |
Even a clean headline/VII beat is largely discounted after a ~20% YTD run into the print (stock ~$96 near highs). The beat is heavily VII-flattered; management continues to guide VII toward a lower normalized run-rate, so out-period math implies forward EPS estimates get trimmed rather than raised despite the Q2 beat. Combined with elevated expectations and quality-of-earnings scrutiny (group non-medical health, RIS spread compression on a flat curve), the likely pattern is a modest sell-the-news day-1 reaction that continues to drift lower over the week as revisions catch up to the normalization narrative. |
LOW |